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A. IntroductIon
The Global HIV Vaccine Enterprise convened a two-day workshop 
on August 10-11 2009, at the Fred Hutchison Cancer Research Center 
offices in Seattle, WA, to discuss the application of novel approaches, 
including systems biology, to HIV vaccine research and development. 
The goals of this Working Group were to identify key scientific issues 
and opportunities that have emerged since the Enterprise Scientific 
Strategic Plan1 was published in 2005, and to make recommendations 
to Enterprise stakeholders.
Earlier this year, for the first time in the more than three decades since 
the discovery of HIV, a candidate HIV vaccine was shown to protect a 
modest proportion of volunteers2 from HIV acquisition, revitalizing 
a field that has been humbled by repeated failure. A large number of 
questions has been raised by this trial, the most important being what 
caused this modest effect on protection from acquisition. The nature of 
the immunological parameters that gave rise to this result is unknown, 
highlighting the urgent need to understand the pathways that must be 
activated to elicit the immune responses necessary to prevent and/or 
control HIV infection. We will argue here that the new tools of systems 
biology, when combined with current approaches, will be transforma-
tive in understanding the molecular networks underlying the immune 
response to HIV infection and will enable strategies to re-engineer these 
networks to generate protective immunity3,4. 
It is important to recognize the critical interplay between technol-
ogy development and biology; when biological questions cannot be 
answered with current technologies, new ones need to be developed 
which, in turn, open new areas of biological inquiry. Novel systems biol-
ogy techniques allow integration of hierarchical levels of information, 
leading to a deconvolution of the complexity of biological systems5. 
These approaches include “omics” measurements, such as genomic, 
transcriptomic, proteomic, metabolomic and lipidomic technologies. 
However, meaningful analyses of large sets of data in a multitude of 
formats also require substantial computational technologies to facili-
tate data visualization, model building and ultimately the capacity to 
simulate the necessary immune responses in silico. Therefore, deploy-
ment of systems biology approaches in HIV vaccine research requires the 
concerted efforts of HIV vaccine researchers, experts in systems biology 
and computational specialists. Initial attempts at applying systems level 
approaches to vaccine development show promise, particularly in defin-
ing molecular signatures induced early after vaccination that correlate 
with and predict the later adaptive immune responses in humans5–7. 
Furthermore, systems approaches are beginning to be applied to under-
standing the mechanisms of action of vaccine adjuvants and vectors8,9. 
Given the preliminary success of these efforts, the Working Group has 
recommended implementation of a coherent suite of structural, organi-
zational, cultural and funding approaches to catalyze integration of novel 
technologies with HIV vaccinology. The Working Group also discussed 
the need for development of new technologies and for attracting and 
training of new talent. This report summarizes the discussions of the 
Working Group, evaluates current gaps, and proposes recommendations 
for future directions.
B. chAllenges, opportunItIes And the WAy ForWArd
Classical approaches to vaccine development aim to understand a spe-
cific property of a pathogen or a specific immunological response that 
might be exploited to develop a vaccine capable of eliciting long-lived 
protection against that pathogen. However, the intrinsic complexity of 
the immune system presents a barrier to understanding how a coordi-
nated and integrated immune response can lead to protective immunity 
against HIV. More recently, new approaches have been developed that 
allow exploration of the complex, interconnected networks involved in 
immune responses to viruses such as HIV. These approaches have the 
potential to transform the field from the search for a single correlate of 
protection to identification of the multifactorial signatures associated 
with immunological protection and provide clues to protective mecha-
nisms.
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of measurements required for integrative analysis that allows com-
parison between different studies; (iii) common regulatory norms 
for informed consent and for data and specimen sharing, ensur-
ing protection of volunteers involved; and (iv) data upload strate-
gies, architecture, ontologies and user-friendly interfaces. Second, 
Enterprise stakeholders need to establish a process for coordinated 
and systematic data and sample collection, storage, and distribution 
to ensure prompt access for projects serving a larger aim of HIV vac-
cine research. This coordinated approach could be assisted through a 
central facility, a contract research organization with global reach, or 
a laboratory responsible for quality assurance for each of the agreed 
upon various measurements, with a transparent process to ensure 
access to the samples and database(s).
priority 2: to create a global data sharing infrastructure for 
data storage and analysis
Large amounts of data are generated in HIV vaccine research. 
Therefore, rapid data sharing is essential to take full advantage of 
this large amount of information. Furthermore, systems biology 
approaches, which have the potential to accelerate multidisciplinary 
integrative analysis, depend on a culture of data sharing. For example, 
integration of genomics and immunological data will provide insights 
into the contribution of host genetics that might underlie population 
variability of vaccine-induced responses. The field needs to craft a 
standard data and reagent sharing agreement that is achievable and 
broadly supported. In addition, appropriate infrastructure will be 
necessary for data deposition, storage, access, and analysis. Multiple 
databases already exist in the HIV vaccine field and the challenges 
in making them accessible to a broader scientific community are 
numerous. They include connecting databases in a way that allows 
integration of diverse data types, providing access to data without 
compromising privacy of subjects and developing user-friendly tools 
and interfaces that allow data visualization and analysis.
While open data sharing is ideal from the perspective of the sci-
entific community, it should be recognized that clinical research is 
always connected to the rights and privacy concerns of study volun-
teers. Clear transparent guidelines need to be developed and com-
In the discussions of this Working Group, four priority areas were 
identified that are critical to harness and integrate novel approaches 
and technological advances into HIV vaccine research and develop-
ment (Table 1).
priority 1: to collect and integrate quantitative data on 
human immunity in normal, vaccinated, and infected 
individuals and the process of hIV transmission and 
dissemination
Clinical trials and human cohorts provide invaluable insights into 
human immunology, immune responses to vaccination and pro-
cesses of HIV transmission and dissemination. Thus, we propose 
that “omics” technologies be actively applied to collect data on the 
human immune system, especially in cases where it is perturbed by 
either vaccination and/or infection.
To facilitate collection and integration of data from different studies, 
a harmonized minimal set of clinical, immunological, and virological 
parameters needs to be identified and adopted by the field (including 
protocols, data upload strategies and ontologies). Whether stored in 
a single database or in a collection of databases, the data from the 
diversity of assays, time points and sources needs to be annotated, 
inter-related, and made available for analyses in ways that will allow 
comparison of data and assays.
We recognize that some aspects of HIV infection and early events 
following vaccination are not amenable to detailed and systematic 
analysis in humans using current technologies. Therefore, we need 
to both develop new and make better use of existing model systems 
(non-human primates (NHP), mice, ex vivo human tissue and oth-
ers). Insights gained from these model systems will help to identify 
mechanisms involved in immune protection in humans.
recommendations
This priority involves a two-step implementation strategy. First, 
scientists from within and outside of the HIV vaccine field should 
be brought together to define and agree on a number of issues 
which include: (i) appropriate population cohorts for both immu-
nological and virological studies; (ii) the minimal harmonized set 
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table 1  summary of priorities and recommendations
priority 1: to collect and integrate quantitative data on human immunity in normal, vaccinated, and infected individuals and the process of hIV transmission and 
dissemination.
• Scientists from within and outside of the HIV vaccine field to define:
  (i) appropriate population cohorts for both immunological and virological studies;
  (ii) the minimal harmonized set of measurements required for integrative analysis that allows comparison between different studies;
  (iii) common regulatory norms for informed consent and for data and specimen sharing, ensuring protection of volunteers involved; and
  (iv) data upload strategies, architecture, ontologies and user-friendly interfaces
• Funders and institutions need to establish a process for coordinated and systematic data and sample collection, storage, and distribution to ensure prompt 
access for projects serving a larger aim of HIV vaccine research.
priority 2: to create a global data sharing infrastructure for data storage and analysis.
• Support a cultural shift in the field to foster data sharing by creating co-ordinated, integrated, harmonized and quality-controlled databases (including long-term 
funding for technological support and computational infrastructure).
priority 3: promote iterative rational vaccine design and evaluation by development, dissemination, and implementation of novel computational, systems biology, 
and technological tools in pre-clinical and clinical studies.
• Use a combination of in silico, in vitro platforms, NHP models and human trials to promote systematic evaluation of candidate vaccine components and immune 
engineering strategies.
• Invest in development and commercialization of technologies identified in the priority.
priority 4: Build capacity by attracting and developing talent, including scientists from resource-limited settings and from outside the field.
• Establish and fund long-term programs that bring together systems biologists, vaccinologists, immunologists, virologists and epidemiologists.
• Create mechanisms to strengthen career development pathways for young and early career investigators.


































priority 4: Build capacity by attracting and developing talent, 
including scientists from resource-limited settings and from 
outside the field
Ensuring that HIV vaccine research benefits fully from the ongoing 
revolution in biomedical research requires input from researchers out-
side the field, technology developers, and computer modelers, as well as 
active involvement from scientists in endemic regions. The HIV vaccine 
research field is considerably more collaborative and multidisciplinary 
now than in 2005, when the first Enterprise Plan was published; how-
ever, the Working Group members felt that even more effort is needed 
to embrace the priorities and accomplish the recommendations in this 
Report. The field needs to harness expertise from other fields of bio-
medical research, as well as to nurture a new generation of scientists. 
In addition, sustainable capacity for HIV vaccine research in resource-
limited countries needs to be built by engaging local government and 
industry as full partners in HIV vaccine research and development. 
Governments and industry should be encouraged to provide long-term 
commitments to develop and maintain research infrastructure, create 
defined career paths, and ensure that young and early-career investiga-
tors receive the mentorship and support they need.
recommendation
Establish and fund long-term programs that bring together systems 
biologists, vaccinologists, immunologists, virologists and epidemiolo-
gists. Create mechanisms to strengthen career development pathways 
for young and early career investigators. Invest in capacity building in 
resource-limited countries that is focused on long-term solutions that 
involve local financial and organizational support.
c. conclusIons
HIV vaccine research and development is at a crossroads, and there is a 
critical need for new approaches to build on recent advances in the field. 
A systems biology approach to HIV vaccine research and development 
aims to integrate quantitative information on the biology, immunology 
and epidemiology of HIV infection and transmission into predictive 
models which support the rational design and testing of novel vaccine 
strategies. The multidisciplinary nature and iterative approach of sys-
tems biology distinguishes it from the linear discover-develop-deliver 
pipeline of empirical vaccinology. In addition, exploiting new oppor-
tunities provided by systems biology is contingent on engagement of a 
considerably wider research community with different skills and ideas. 
Systems biology offers a potentially fruitful strategy that can make a dif-
ference at a number of levels, including identification of the signatures 
of immune protection, identification of novel adjuvants and vectors, and 
the scientific insights that will enable rational vaccine design.
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municated effectively to participating communities guaranteeing 
protection of their rights while maximizing public benefit. Field-wide 
adoption of these guidelines will contribute to building community 
trust and will greatly facilitate our ability to share, integrate and ana-
lyze datasets collected by different research groups.
recommendation
Support a cultural shift in the field to foster data sharing by creating 
co-ordinated, integrated, harmonized and quality-controlled data-
bases (including long-term funding for technological support and 
computational infrastructure). A working group representing differ-
ent Enterprise stakeholders and experts could discuss and agree on 
technological, regulatory and ethical issues surrounding creation of 
such relational databases.
priority 3: promote iterative rational vaccine design 
and evaluation by development, dissemination, and 
implementation of novel computational, systems biology and 
technical advances in pre-clinical and clinical studies
Rational vaccine design and testing will benefit from the develop-
ment and integration of novel computational, systems biology and 
technical advances in pre-clinical and clinical studies. Systems biology 
approaches depend upon the iterative process of developing compu-
tational models and testing of these models in situations where the 
modeled system can be perturbed. Thus, the focus of these efforts 
should be on modeling the interplay between viral infection and 
immune responses, as well as on analysis of timing, location, and 
extent of vaccine-induced immune responses. When applied in this 
manner, computational approaches will give valuable insights into 
the mechanisms of infection and protection, complementing and 
building on the knowledge gained in pre-clinical and clinical stud-
ies. Additionally, these novel tools will be useful when designing and 
performing integrative studies to re-engineer immune responses for 
the desired outcome in different in vitro and in vivo models.
In addition to efforts in computational and systems biology 
approaches, it is critical to develop and disseminate novel tools and 
assays to answer questions that cannot be readily addressed by current 
approaches. We need to support the development and utilization of 
high-throughput technology platforms, novel cellular and molecu-
lar assays for immune cells and mediators, ultra-high-throughput 
sequencing, single cell fluidic analyses, and non-invasive/minimally-
invasive imaging technologies for analysis of in situ/in vivo responses 
to HIV infection and to vaccination. Also, we stress the importance 
of developing robust technologies for sample collection and pheno-
type measurement applicable in resource-limited settings, including 
barcoding, RNA, protein, lipid and cytokine analysis and appropriate 
sample storage to ensure data quality and standards.
recommendation
Use a combination of in silico, in vitro platforms, NHP models and 
human clinical trials to promote systematic evaluation of candidate 
vaccine components and immune engineering strategies. This rec-
ommendation could be implemented by engaging systems biology 
approaches in the design of clinical trials, incorporating “omics” 
approaches to collect comprehensive data on vaccinees and con-
trols, and providing inter-related data to the scientific community 
for exploration and generation of novel hypotheses. Investments in 
development and commercialization of technologies identified in the 
priority above will also be required.
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